GAMA
PTGX icon

Graticule Asia Macro Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Graticule Asia Macro Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-29,027
Closed -$328K – 116
2017
Q2 		$328K Sell
29,027
-2,800
-9% -$29.9K 0.02% 108
2017
Q1 		$408K Hold
31,827
– – 0.02% 115
2016
Q4 		$700K Hold
31,827
– – 0.08% 90
2016
Q3 		$673K Buy
+31,827
New +$435K 0.05% 88

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Graticule Asia Macro Advisors's PTGX Position: Q3 2017 in Review

Graticule Asia Macro Advisors sold out of Protagonist Therapeutics (PTGX) in Q3 2017, closing a stake of 29,027 shares — an estimated $328K sold.

Graticule Asia Macro Advisors first reported a position in PTGX in Q3 2016 and held it in 4 quarters. The position peaked at $700K in Q4 2016. 41 funds tracked by Wall St. Rank hold PTGX as of Q3 2017.

  • Graticule Asia Macro Advisors reported no remaining Protagonist Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 29,027 Protagonist Therapeutics shares in Q3 2017, an estimated $328K.
  • Graticule Asia Macro Advisors first reported a position in Protagonist Therapeutics in Q3 2016 and held it in 4 quarters.
  • Graticule Asia Macro Advisors's Protagonist Therapeutics position peaked at $700K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.